PMID: 42138103

Orforglipron and the emergence of oral GLP-1 therapy for obesity: efficacy, safety, and clinical positioning.

Zaman Wajid, Amin Adnan

Expert opinion on pharmacotherapy · 2026

Vol. 27, Issue 8, pp. 697-708

View on PubMedDOI

This entry links to third-party literature. For research use only.

HumansObesityAdministration, OralAnti-Obesity AgentsGlucagon-Like Peptide-1 Receptor AgonistsAnimalsQuality of LifeWeight LossIncretinsGlucagon-Like Peptide 1

For research use only. This index links to third-party literature. Nothing here constitutes medical advice.